Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
03 November 2022 - 2:07PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that six abstracts have been accepted for
presentation, including two oral presentations, at the 64th
American Society of Hematology (ASH) Annual Meeting to be held
December 10-13, 2022 in New Orleans, LA.
“The presentations at ASH will showcase the potential for both
our allogeneic CAR T cell and in vivo delivery platforms to develop
differentiated drugs for patients with hematologic malignancies,”
said Terry Fry, Sana’s Senior Vice President and Head of T Cell
Therapeutics. “We are initially developing therapeutics for
patients with lymphoma, leukemia, and multiple myeloma, and we look
forward to presenting data on CD19-, CD22- and BCMA-targeted
therapeutic candidates at the meeting.”
Details of the oral presentations are as follows:
Title: |
|
Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in
Fully Immunocompetent Allogeneic Humanized Mice |
Abstract
Number: |
|
485 |
Session
Name: |
|
703. Cellular Immunotherapies:
Basic and Translational IV |
Session
Date: |
|
Sunday, December 11, 2022 |
Session
Time: |
|
9:30 – 11:00 a.m. CT |
Presentation
Time: |
|
10:30 a.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, 388-390 |
Presenter: |
|
Sonja Schrepfer, PhD |
Title: |
|
Efficient and Specific Multi-Locus Editing of Allogeneic CAR T
Cells for Hypoimmunity during Large Scale Manufacture Using
Cas12b |
Abstract
Number: |
|
663 |
Session
Name: |
|
711. Cell Collection and
Processing I |
Session
Date: |
|
Sunday, December 11, 2022 |
Session
Time: |
|
4:30 – 6:00 p.m. CT |
Presentation
Time: |
|
5:00 p.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, 220-222 |
Presenter: |
|
Christina Chaivorapol, PhD |
Details of the poster presentations are as follows:
Title: |
|
Functional T Cell Assays Are Predictive of Pre-Clinical Potency to
Generate Allogeneic, Hypoimmune CD19 CAR T Cells |
Abstract
Number: |
|
1974 |
Session
Name: |
|
703. Cellular Immunotherapies:
Basic and Translational: Poster I |
Session
Date: |
|
Saturday, December 10, 2022 |
Session
Time: |
|
5:30 – 7:30 p.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, Hall D |
Presenter: |
|
Darin Salloum, PhD |
Title: |
|
A
Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate
and Adaptive Immune Rejection and Overcome Antigen Escape |
Abstract
Number: |
|
1988 |
Session
Name: |
|
703. Cellular Immunotherapies:
Basic and Translational: Poster I |
Session
Date: |
|
Saturday, December 10, 2022 |
Session
Time: |
|
5:30 – 7:30 p.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, Hall D |
Presenter: |
|
Adam Johnson, PhD |
Title: |
|
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent
Anti-Tumor Activity Together with the Ability to Evade Innate and
Adaptive Immune Rejection in Pre-Clinical Tumor Models |
Abstract
Number: |
|
3168 |
Session
Name: |
|
651. Multiple Myeloma and Plasma
Cell Dyscrasias: Basic and Translational: Poster II |
Session
Date: |
|
Sunday, December 11, 2022 |
Session
Time: |
|
6:00 – 8:00 p.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, Hall D |
Presenter: |
|
Jeremy Kinder, PhD |
Title: |
|
CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells
and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell
Therapies |
Abstract
Number: |
|
3457 |
Session
Name: |
|
801. Gene Therapies: Poster
II |
Session
Date: |
|
Sunday, December 11, 2022 |
Session
Time: |
|
6:00 – 8:00 p.m. CT |
Location: |
|
Ernest N. Morial Convention
Center, Hall D |
Presenter: |
|
Jesse Green, PhD |
Full abstracts are available for online viewing via the ASH
Annual Meeting website at
www.hematology.org/meetings/annual-meeting. In addition, abstracts
will be published online in the November supplemental issue of
Blood, the journal of the American Society of Hematology.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for the Company’s participation at the
64th American Society of Hematology Annual Meeting and Exposition;
and expectations for the Company’s presentations at such
conference, including regarding the content of such presentations.
All statements other than statements of historical facts contained
in this press release, including, among others, statements
regarding the Company’s strategy, expectations, cash runway and
future financial condition, future operations, and prospects, are
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as the economic,
market and social disruptions due to the ongoing COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Quarterly Report on Form 10-Q dated November 2,
2022. Except as required by law, the Company undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024